COMMUNIQUÉS West-GlobeNewswire

Mapi Pharma Presents Phase II Extension Results of Glatiramer Acetate Depot (GA Depot) at ECTRIMS 2018 in Berlin
09/10/2018
81.8% Patients on GA Depot Demonstrated No Evidence of Disease Activity (NEDA) at 2 years GA Depot Has Potential to Address Multiple Sclerosis Treatment Burden and Improve Patient Compliance NESS ZIONA, Israel, Oct. 09 [...]
Agile Therapeutics, Inc. Completes Formal Dispute Resolution Process with the FDA
09/10/2018
PRINCETON, N.J., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it has received a response from FDA’s Office of New Drugs (“OND”) concerning [...]
Poseida Therapeutics Appoints Marcy Graham as Vice President, Corporate Affairs
09/10/2018
SAN DIEGO, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today announced Marcy Graham has [...]
Ceapro Inc. Receives Approval from Health Canada to Commence Human Clinical Study Assessing Beta Glucan as a Cholesterol-Lowering Agent
09/10/2018
– Ceapro is Pioneering approach with a natural product as add-on therapy to a prescription product – First of the clinical studies being conducted as part of collaboration with the Montreal Heart Institute led by MHI’s [...]
Oryzon announces first patient enrolled in REIMAGINE: a Phase IIa clinical trial with Vafidemstat (ORY-2001) in aggressiveness
09/10/2018
MADRID, Spain and CAMBRIDGE, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), (“Oryzon”), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop [...]
Coherus BioSciences Announces New Employment Inducement Grants
09/10/2018
REDWOOD CITY, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective October 8, 2018, the compensation committee of the company’s board of directors granted 65 [...]
OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of Clinical Oncology Meeting
09/10/2018
REDWOOD CITY, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today [...]
Medovex Corporation Names William E. Horne Chief Executive Officer and Chairman of the Board
09/10/2018
Seasoned Healthcare Industry Veteran, Founder and Former Chief Executive Officer of Laser Spine Institute to Lead Company Growth Initiative ATLANTA, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Medovex Corp. (OTCQB: MDVX), (" [...]
BioCorRx, Inc. Announces Preliminary Agreement with VDM Biochemicals to Develop and Commercialize Patented Opioid Antagonist VDM-001
09/10/2018
ANAHEIM, CA, Oct. 09, 2018 (GLOBE NEWSWIRE) -- VDM-001 represents potential alternative to naloxone for overdose reversal ; Potential to reduce cravings from substance use disorder via NEWMEDIAWIRE -- BioCorRx Inc. ( [...]
OV: Oncology Venture to Participate at Upcoming Investor Events in Q4 2018
09/10/2018
Investor news Hørsholm, Denmark and Cambridge, MA, US, October 9 th , 2018 - Oncology Venture A/S ("Oncology Venture") today announced that members of its senior management team are scheduled to make a number of [...]
Nu-Med Plus, Inc. Announces Strategic Rebrand to Focus on Leading Advancements in the Nitric Oxide Delivery Industry
09/10/2018
Nu-Med Plus, Inc. inventors of new, portable, lower-cost, and higher-precision nitric oxide delivery technology evolves its strategy as leaders to, “Reinventing the Healing Power of Nitric Oxide Delivery” SALT LAKE CITY [...]
Wave Life Sciences to Develop Programs in Rare, Genetic Eye Diseases
09/10/2018
Research will focus on inherited retinal diseases associated with RHO, USH2A, ABCA4 and CEP290 Initial development candidate expected in H2 2019 CAMBRIDGE, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd [...]
UPDATE - Aleafia to Launch Industry First 60,000 kg Secure Outdoor Grow Expansion
09/10/2018
Low Cost Expansion to Increase Aleafia’s Annual Production Capacity to 98,000 kg TORONTO, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Aleafia Health Inc. ( TSXV: ALEF; OTCQX: ALEAF, FRA: ARAH ) (“ Aleafia ”) or (the “ Company [...]
Myriad and Pfizer Build Upon a Previously Announced Companion Diagnostic Agreement
09/10/2018
Commercialization Plan Now in Place for BRACAnalysis CDx® As a Companion Diagnostic with Pfizer’s Talazoparib SALT LAKE CITY, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in [...]
Resonant Inc. to Introduce New 5G RF Filter Breakthrough at the 2018 IEEE International Ultrasonics Symposium in Kobe, Japan, on October 24th
09/10/2018
GOLETA, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for wireless devices, today announced [...]
IMV Inc. to Present at Upcoming Investor Conferences
09/10/2018
DARTMOUTH, Nova Scotia, Oct. 09, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that Chief Executive Officer Frederic Ors and Chief Financial [...]
Ziopharm and Precigen Redefine Relationships, Announce New License Agreement
09/10/2018
Ziopharm to Host Conference Call at 8 a.m. BOSTON and GERMANTOWN, Md., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) and Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation ( [...]
Radient Technologies Inc. receives Controlled Drugs and Substances Licence for its Manufacturing Facility
09/10/2018
EDMONTON, Alberta, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) ( TSX Venture: RTI ) is pleased to announce that it has received its Controlled Drugs and Substances Licence, [...]
Loxo Oncology Announces Details for Data Presentations at the European Society for Medical Oncology 2018 Congress
09/10/2018
STAMFORD, Conn., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, today announced that [...]

Pages